Location
Philadelphia, PA
Start Date
17-4-2026 1:30 PM
End Date
17-4-2026 2:30 PM
Description
Background: Lithium remains the gold-standard mood stabilizer for bipolar disorder due to its efficacy in reducing mood episodes and suicide risk. However, long-term lithium use has been associated with renal effects, including impaired urinary concentrating ability and chronic kidney disease (CKD). The absolute risk of severe CKD attributable to lithium is modest, but identifying risk factors that predispose patients to renal decline is crucial for personalized monitoring and treatment planning.
Objective: To summarize evidence on patient-level and treatment-related factors associated with increased risk of CKD in individuals treated with lithium for bipolar disorder, and to highlight implications for clinical practice.
Methods: A narrative review was conducted using PubMed and Google Scholar for studies published between 2000 and 2025. Search terms included “lithium nephropathy,” “lithium chronic kidney disease,” “lithium bipolar kidney outcomes,” and “renal risk factors lithium.” Studies reporting renal function outcomes (eGFR, creatinine elevation, end-stage renal disease) in adults with bipolar disorder on lithium were included. Observational cohorts, cross-sectional studies, and systematic reviews were evaluated.
Results: Lithium-associated CKD prevalence varies by cohort design and follow-up duration, with systematic analyses identifying impaired kidney function in ~24–30% of long-term lithium users. Identified risk factors for lithium-related renal decline include:
● Longer duration of lithium therapy: Each additional year of exposure is associated with small but cumulative decreases in estimated glomerular filtration rate (eGFR).
● Higher cumulative lithium dose and serum levels: Elevated trough levels (≥0.8 mmol/L) correlate with steeper eGFR decline.
● Older age at initiation: Patients initiating lithium at age ≥60 have higher rates of eGFR reduction compared to younger cohorts.
● Pre-existing reduced renal function: Baseline eGFR < 60 mL/min/1.73 m² predicts accelerated CKD progression on lithium.
Comorbid conditions: Hypertension and diabetes are associated with additive risk for renal impairment in lithium-treated patients.
Discussion: These findings highlight that while lithium is effective for bipolar disorder, clinicians should be vigilant for known kidney risk factors. The interplay of age, baseline renal function, cumulative exposure, and comorbidities suggests a need for personalized monitoring protocols. Although absolute risk of severe ESRD due solely to lithium remains relatively low compared with risk from aging and other factors, early identification of susceptibility may permit interventions such as dose adjustment, more frequent renal monitoring, or consideration of alternative mood stabilizers in high-risk individuals.
Conclusion: Risk factors for lithium-associated CKD include longer exposure, higher serum lithium levels, older age, reduced baseline renal function, and comorbid hypertension/diabetes. Understanding these factors supports targeted monitoring and may improve shared decision-making in bipolar disorder management.
Embargo Period
6-3-2026
Included in
Risk Factors for Lithium-Induced Chronic Kidney Disease in Bipolar Disorder Patients: A Literature Review
Philadelphia, PA
Background: Lithium remains the gold-standard mood stabilizer for bipolar disorder due to its efficacy in reducing mood episodes and suicide risk. However, long-term lithium use has been associated with renal effects, including impaired urinary concentrating ability and chronic kidney disease (CKD). The absolute risk of severe CKD attributable to lithium is modest, but identifying risk factors that predispose patients to renal decline is crucial for personalized monitoring and treatment planning.
Objective: To summarize evidence on patient-level and treatment-related factors associated with increased risk of CKD in individuals treated with lithium for bipolar disorder, and to highlight implications for clinical practice.
Methods: A narrative review was conducted using PubMed and Google Scholar for studies published between 2000 and 2025. Search terms included “lithium nephropathy,” “lithium chronic kidney disease,” “lithium bipolar kidney outcomes,” and “renal risk factors lithium.” Studies reporting renal function outcomes (eGFR, creatinine elevation, end-stage renal disease) in adults with bipolar disorder on lithium were included. Observational cohorts, cross-sectional studies, and systematic reviews were evaluated.
Results: Lithium-associated CKD prevalence varies by cohort design and follow-up duration, with systematic analyses identifying impaired kidney function in ~24–30% of long-term lithium users. Identified risk factors for lithium-related renal decline include:
● Longer duration of lithium therapy: Each additional year of exposure is associated with small but cumulative decreases in estimated glomerular filtration rate (eGFR).
● Higher cumulative lithium dose and serum levels: Elevated trough levels (≥0.8 mmol/L) correlate with steeper eGFR decline.
● Older age at initiation: Patients initiating lithium at age ≥60 have higher rates of eGFR reduction compared to younger cohorts.
● Pre-existing reduced renal function: Baseline eGFR < 60 mL/min/1.73 m² predicts accelerated CKD progression on lithium.
Comorbid conditions: Hypertension and diabetes are associated with additive risk for renal impairment in lithium-treated patients.
Discussion: These findings highlight that while lithium is effective for bipolar disorder, clinicians should be vigilant for known kidney risk factors. The interplay of age, baseline renal function, cumulative exposure, and comorbidities suggests a need for personalized monitoring protocols. Although absolute risk of severe ESRD due solely to lithium remains relatively low compared with risk from aging and other factors, early identification of susceptibility may permit interventions such as dose adjustment, more frequent renal monitoring, or consideration of alternative mood stabilizers in high-risk individuals.
Conclusion: Risk factors for lithium-associated CKD include longer exposure, higher serum lithium levels, older age, reduced baseline renal function, and comorbid hypertension/diabetes. Understanding these factors supports targeted monitoring and may improve shared decision-making in bipolar disorder management.